Improved retention of endothelial cells seeded on polyurethane small-diameter vascular grafts modified by a recombinant RGD-containing protein.
Sponge-type small-diameter vascular grafts were fabricated from a medical-grade polyurethane, Pellethane 2363-80A, by utilization of a salt casting technique. The grafts were compliance matched with a storage modulus of 0.53 +/- 0.08 MPa. The luminal surface of grafts was modified with a thin layer ( approximately 40 micro m) of gelatin crosslinked by epoxide. Then a special Arg-Gly-Asp (RGD)-containing recombinant protein, named CBD-RGD (cellulose binding domain RGD-containing protein), was coated onto the gelatin layer. The platelet adhesion and activation on such a gelatin/CBD-RGD modified surface was significantly reduced. Human umbilical vein endothelial cells were seeded more efficiently onto the modified grafts. There was also a substantial reduction in the subsequent loss of cells from the graft surface following perfusion in vitro. The cell number retained on the modified graft was enhanced by three times after 1 h of perfusion, and by eight times after 3 h of perfusion (retention rate approximately 63%). The retention after 3 h of perfusion could be further increased to nearly 100% if the lined endothelium on gelatin/CBD-RGD modified graft was cultured for another week before perfusion. The modified surface was also shown to help canine external jugular vein endothelial cells to maintain the round cell morphology in vitro.
Hsu
Shan-Hui
SH
Department of Chemical Engineering; and Institute of Veterinary Microbiology, National Chung Hsing University, Taichung, Taiwan, Republic of China. shhsu@nchu.edu.tw
Sun
Sung-Huan
SH
Chen
David Chanhen
DC
D000818:Animals; D001672:Biocompatible Materials / Q000494:pharmacology*; D001807:Blood Vessel Prosthesis; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D002482:Cellulose / Q000494:pharmacology; D004285:Dogs; D042783:Endothelial Cells / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D009842:Oligopeptides / Q000494:pharmacology*; D015539:Platelet Activation / Q000187:drug effects / Q000502:physiology; D011140:Polyurethanes / Q000494:pharmacology*; D011474:Prosthesis Design; D023822:Tissue Engineering / Q000379:methods
D001672:Biocompatible Materials; D009842:Oligopeptides; D011140:Polyurethanes; C047981:arginyl-glycyl-aspartic acid; D002482:Cellulose